SEC Comment Letter for HCW Biologics Inc. (HCWB) (CIK 0001828673) (HCWB) — Aug 26, 2026

HCW Biologics Inc. (HCWB) (CIK 0001828673)
Date: Aug. 26, 2026 · CIK: 0001828673 · Accession: 0000000000-26-008417

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-298452

Date

August 26, 2026

Author

Division of

Form

UPLOAD

Company

HCW Biologics Inc. (HCWB) (CIK 0001828673)

Letter

Re: HCW Biologics Inc. Registration Statement on Form S-1 Filed August 20, 2026 File No. 333-298452 Dear Hing C. Wong: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions.

August 26, 2026

Hing C. Wong Chief Executive Officer HCW Biologics Inc. 2929 N Commerce Parkway Miramar, FL 33025

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: James Groth, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                            August 26, 2026

Hing C. Wong
Chief Executive Officer
HCW Biologics Inc.
2929 N Commerce Parkway
Miramar, FL 33025

        Re: HCW Biologics Inc.
            Registration Statement on Form S-1
            Filed August 20, 2026
            File No. 333-298452
Dear Hing C. Wong:
       This is to advise you that we have not reviewed and will not review your
registration
statement.
       Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you that
the company and its management are responsible for the accuracy and adequacy of
their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
       Please contact Tyler Howes at 202-551-3370 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    James Groth, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io